FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Described is a group of inventions comprising a humanized, murine and chimeric antibodies or fragments thereof specifically binding to a peptide with SEQ ID NO: 1, wherein said peptide is directed to cell surface in virus-infected cells, a polynucleotide encoding said antibodies, an expression vector, a host cell for expressing said antibodies, a method of producing said antibodies, antiviral composition and a composition for preventing or treating inflammatory diseases caused by a viral infection, containing said antibodies, a method of treating infectious viral diseases and a method of treating inflammatory diseases caused by a viral infection.
EFFECT: invention extends the range of agents for binding with a peptide with SEQ ID NO: 1, wherein said peptide is directed to cell surface in virus-infected cells.
30 cl, 58 dwg, 17 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| ANTIBODIES USED PASSIVE VACCINATION AGAINST INFLUENZA | 2012 |
|
RU2668802C2 |
| ANTIBODIES AGAINST A5 REPRESENTATIVE OF 19 FAMILY WITH SIMILARITY OF SEQUENCES AND THEIR APPLICATION METHOD | 2019 |
|
RU2785436C2 |
| HIGH-AFFINITY HUMAN ANTIBODIES TO CYTOMEGALOVIRUS (CMV) gB PROTEIN | 2011 |
|
RU2613421C2 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| ANTIBODY AGAINST TIE-2 AND ITS USE | 2020 |
|
RU2795455C2 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA | 2011 |
|
RU2635999C2 |
| STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE | 2016 |
|
RU2754041C2 |
| ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
| RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTI-G PROTEIN ANTIBODIES | 2008 |
|
RU2526517C2 |
